Affinia Therapeutics

Rick Modi, President and CEO 

Oct. 11 | 11:45am | Rentschler ATMP Ballroom 

Waltham, MA 


Affinia Therapeutics is pioneering a shift to a new class of rationally designed gene therapies that treat rare and prevalent devastating diseases. Affinia Therapeutics’ proprietary Affinia rationally designed Therapeutics (ART) platform consists of three pillars intended to synergistically improve the efficacy, safety, and manufacturability of adeno-associated virus (AAV)-based gene therapies through the development of next-generation capsids, promoters, and manufacturing approaches.

By using this website you agree to accept our Privacy Policy and Terms & Conditions